Background and objectives Higher left ventricular volume is associated with death in patients with ESRD. This work investigated the effects of frequent hemodialysis on ventricular volumes and left ventricular remodeling.
Introduction
Cardiovascular disease is the leading cause of death in patients with ESRD, with rates of cardiovascular death 10-to .100-fold higher than in the agematched general population (1) . An increase in left ventricular (LV) cavity size is independently associated with mortality and cardiovascular morbidity in ESRD (2, 3) . Few interventions have been shown to reduce a pathologically enlarged LV cavity in the ESRD patient population (4) . Putative risk factors leading to LV dilation in ESRD include volume overload, anemia, high-flow arteriovenous fistulae, and poorly controlled uremia (5) .
Ventricular remodeling is defined as "molecular, cellular and interstitial changes that are manifested clinically as changes in size, shape and function of the heart after cardiac injury" (6) . At a cellular level, the process of cardiac myocyte hypertrophy combined with altered interstitial fibrosis, apoptosis, or necrosis is influenced by hemodynamic and neurohormonal changes secondary to the injurious stimuli. Impact of interventions on LV remodeling has become an important outcome measure. As a result, in addition to LV cavity size, the ratio of LV mass to LV end diastolic volume (EDV; a marker of LV remodeling) has become an important prognostic indicator in the non-ESRD population (7) . In the setting of ESRD, changes in BP and interdialytic weight gain as well as surrogate markers of clearance (e.g., serum phosphorus) may be of particular interest given the emerging literature linking these factors to progression of LV mass, LV cavity size, or both (8) (9) (10) (11) (12) . The effects of frequent hemodialysis on ventricular volumes and the ratio of LV mass to LVEDV is unknown.
The Frequent Hemodialysis Network (FHN) trials aimed to examine the effects of frequent (six times per week) hemodialysis (in the form of in-center daily hemodialysis or nocturnal home hemodialysis) versus conventional three times weekly hemodialysis on multiple intermediate outcome measures (13) (14) (15) .
The objectives and protocol summaries of both trials have been previously published (15) . Owing to limitations in sample size, the FHN trials were not designed to assess the effects of frequent hemodialysis on death or major health events. Nine prespecified domains were identified by the investigators, including one domain related to cardiac structure and function. We previously identified determinants of change in LV mass with frequent hemodialysis (11) . However, changes in cardiac ventricular volume and LV remodeling had not been explored.
The primary objective of the present report was to describe the effects of frequent hemodialysis on LV and right ventricular (RV) volumes, LV remodeling (as determined by LV mass/LVEDV), and global systolic function (as assessed by ejection fraction) and explore which (if any) baseline patient characteristics seem to modify such an effect. We also aimed to explore potential mechanistic pathways (including control of hypertension, magnitude of ultrafiltration, residual kidney function, and control of retained uremic solutes) that might explain the therapeutic response to frequent hemodialysis.
Materials and Methods

FHN Trials
The FHN daily and nocturnal trials were multicenter, randomized, prospective trials of in-center daily hemodialysis and home nocturnal hemodialysis, respectively, sponsored by the National Institutes of Health, National Institutes Diabetes, Digestive and Kidney Diseases and the Center for Medicare and Medical Services. The designs and inclusion and exclusion criteria of both daily and nocturnal trials were described previously (15, 16) . Of note, the residual kidney function exclusion criterion was higher in the nocturnal trial (average of urea and creatinine clearance.10 ml/min per 1.73 m 2 ) than the daily trial (urea clearance.3 ml/min per 35 L). Patients were enrolled between March of 2006 and May of 2009, and the trials concluded in May of 2010. Both trials were approved by the local institutional review board at each participating site. An independent Data Safety Monitoring Board provided oversight of both trials (ClinicalTrials.gov numbers: NCT00264758 and NCT 00271999).
Dialysis Intervention
Patients in the conventional arm of both trials remained on their usual three times per week hemodialysis prescription subject to a prescribed equilibrated Kt/V urea .1.1, a standardized Kt/V urea .2.0, and a treatment time$2.5 h/session. Patients randomized to the frequent arm of the daily trial were targeted to an equilibrated Kt/Vn=0.9, where Vn=3.2713V 2/3 , provided that the length of the session was between 1.5 and 2.75 hours. Patients randomized to the frequent arm of the nocturnal trial followed hemodialysis prescriptions subject to a standardized Kt/V urea $4.0 and a treatment time$6 hours (72 of 87 patients in the nocturnal trial received therapy at home rather than in center).
Cardiac Magnetic Resonance Imaging
We measured LV mass (LVM) and biventricular volumes by cardiac magnetic resonance imaging (CMRI) in all randomized patients at baseline and 12 months where feasible.
All CMRI images were analyzed centrally in a blinded manner. CMRI was performed on 1.5 T MRI systems (minimum gradient performance: peak strength$12 mT/m, slew rate$40 mTm/s) with dedicated surface coils. Sites were required to use standardized protocols using breathheld, retrospective electrocardiogram-gated steady state free precession imaging in contiguous short-axis views (8-mm slice thickness and 2-mm gap) that were carefully prescribed from localizer long-axis images. Imaging parameters were adjusted on each specific CMRI scanner to provide 20-25 cardiac phases, with an in-plane spatial resolution superior#2 mm and a temporal resolution,50 ms. Using validated software (Argus; Siemens Medical Solutions, Erlangen, Germany), we measured myocardial volume on end diastolic frames by manual tracing of endocardial and epicardial contours. We excluded papillary muscles from the calculation of myocardial mass. Subsequently, this volume was multiplied by the specific density of the myocardium (1.05 g/cm 3 ) to obtain LVM (17) . Similarly, we traced biventricular endocardial contours in end diastole and end systole to derive EDV and end systolic volume (ESV). We used the formula in the work by DuBois and DuBois (18) to index LVM to body surface area. We calculated anthropometric volume using the equation in the work by Watson et al. (19) 
CMRI Outcome Measures
Change in LV and RV Volumes and LVM/LVEDV. We assessed the effect of frequent hemodialysis on LV and RV volumes by examining the differences in LV and RV ESVs and EDVs and the percent change of the geometric mean of these parameters at baseline and 12 months. The treatment effect of frequent hemodialysis on LV remodeling was assessed by examining the differences in LVM and LVM/ LVEDV at baseline and 12 months.
Subgroup Analyses. We a priori categorized nine subgroups to explore whether baseline demographic or clinical variables modified the effect of frequent hemodialysis on change in cardiac volumes and LVM/LVEDV. These baseline subgroups were age (#50 or .50 years), sex, anthropometric total body water volume (#40 or .40 L), vintage of ESRD (,4 or $4 years), urine volume (,100 or $100 ml [daily trial] and #500 or .500 ml [nocturnal trial]), race (black or white), baseline LVM (,132 or $132 g), baseline congestive heart failure (yes or no), and diabetes status (yes or no). Given that medications may also influence ventricular volumes and LV remodeling, baseline use of b-blockers (yes or no) and renin-angiotensin blockade (yes or no) was also considered.
Intermediate Outcomes Considered in Correlational Analyses. We a priori defined intermediate measures reflecting each of the three proposed mechanistic pathways leading to cardiac dilation: predialysis systolic BP, interdialytic weight change, and predialysis serum phosphorus concentration.
Data Analysis
Descriptive statistics for continuous variables were summarized using mean 6 SD or medians and 10th and 90th percentiles as appropriate. Categorical variables were summarized using frequencies and proportions. Descriptive summaries of changes in treatment-related variables are provided for the constant cohort with nonmissing values at baseline and 12 months after randomization. Because of positive skewness, the variables LVEDV, LVESV, RDEDV, and RVESV were each log-transformed before statistical analyses. For these outcomes, estimates of mean changes and treatment effects were expressed as percent differences in geometric means. The effects of randomized treatment assignment on cardiac volumes and LV remodeling were estimated by applying a mixed effects model to baseline and 12-month values using an unstructured covariance matrix with covariate adjustment, including a time interaction for the baseline outcome measures, plus prespecified covariates age, diabetes, and clinical center for the daily trial and age, diabetes, and baseline GFR for the nocturnal trial (11) . Because outcomes were assessed at a single follow-up time, this model produced results essentially identical to an analysis of covariance relating the change in the outcome to treatment assignment controlling for the baseline value of the outcome.
We addressed the possible role of the timing of the MRI measurements in relation to the dialysis treatment schedule by summarizing the distribution of the time interval between the MRI measurement and the end of the preceding dialysis treatment; we compared this distribution with the distribution of the average interdialytic interval between dialysis treatments in the week preceding the baseline and 12-month kinetic modeling sessions.
For each of nine prespecified factors, we used separate linear regression analyses to relate the change in LV and RV EDVs to treatment assignment, prespecified baseline covariates, and corresponding interaction terms. The primary assessment of treatment interactions with quantitative subgroup factors was based on a test for linear interaction, which treated the subgroup factor as a continuous variable; estimated treatment effects are also provided for the subgroups defined by the above indicated cutoffs for descriptive purposes. In the daily trial, we present P values for the interactions without adjustment for multiple comparisons. Because of its limited sample size, we considered subgroup analyses in the nocturnal trial in an exploratory fashion without significance testing.
We depicted the association of changes in LV and RV EDVs with changes in average sessional interdialytic weight change, predialysis systolic BP, and predialysis phosphorus for individual patients using scatterplots with separate nonparametric local regression curves (20) for each treatment group. We also provided Pearson correlations between the changes for each group. The end of study levels of average sessional interdialytic weight change, predialysis systolic BP, and serum phosphorus were averaged over measurements at months 10-12.
We performed all analyses using SAS version 9.2. We considered two-tailed P values,0.05 as statistically significant.
Results
The FHN trials randomized 245 patients to 12 months of frequent versus conventional in-center hemodialysis and 87 patients to 12 months of frequent home nocturnal versus conventional (predominantly at home) hemodialysis.
Selected baseline demographics, clinical characteristics, cardiovascular risk profile, medication use, and biochemical status are summarized in Table 1 . In the daily trial, 5 patients died, and 11 patients were transplanted in the frequent arm; corresponding numbers were 9 and 13, respectively, in the conventional arm. In the nocturnal trial, two patients died, and three patients were transplanted in the frequent arm; corresponding numbers were one and zero, respectively, in the conventional arm. Baseline median volumetric and global contractile indices for the RV and LV are depicted in Table 2 .
Effect on Cardiac Volumes and LV Remodeling
In with the conventional group. There were no significant differences between groups in ejection fraction. In the nocturnal trial, there were no significant treatment differences in changes in LV and RV volumes or ejection fractions ( Figure 1 and Table 2 ). Overall, there did not seem to be major differences in the timing of MRI scans relative to the preceding dialysis treatment at baseline or the end of the study in either trial (Supplemental Table 1 ).
We have previously reported that, in the daily trial, frequent hemodialysis resulted in a significant relative reduction in LVM (213.1 g [25.0 to 221.3 g], P=0.002). LVM also seemed to fall in the nocturnal trial (210.1 g [223.7 to 1.8 g], P=0.09). However, the ratio of LVM to LVEDV did not change in either trial (Table 2) .
Subgroup Analyses
Among nine prespecified factors, only residual urine volume was shown to be an important effect modifier for LVEDV. In the daily trial, there was a consistent trend showing a more pronounced treatment effect among patients with lower baseline residual urine volume (P=0.02) ( Figure 2 and Table 3 ).
Correlational Analyses
Within each treatment group in the daily and nocturnal trials, those patients with larger reductions in LVEDV tended to have larger reductions in predialysis systolic BP ( Figure 3 and Table 4 ). There was no association between changes in LVEDV and changes in interdialytic weight gain or changes in serum phosphorus.
Similar relations were noted for changes in RVEDV and reduction in predialysis systolic BP in the daily and nocturnal trials. In addition, changes in RVEDV tended to track with changes in interdialytic weight gain in both trials (Table 4) .
Evolution of LVM and LVEDV
Within each trial, we examined the changes in LVM in concert with LVEDV. Overall, of the patients who received frequent hemodialysis, the highest proportion of these participants had reductions in both LVM and LVEDV in both daily and nocturnal trials (Figure 4 ).
Discussion
LV dilation is an independent determinant of cardiac mortality in patients with ESRD (21) . The present study extends observations in these earlier studies and provides precise estimates of the magnitude of reduction in LV and RV volumes by frequent hemodialysis using CMRI. In addition, we documented the evolution of LVM and volume with frequent hemodialysis. Our data also provide insights into the determinants of changes in LV and RV volumes with frequent dialysis. Results are shown as mean 6 SD or frequency (%) as appropriate. Patients may have more than one hemodialysis access at baseline. COPD, chronic obstructive pulmonary disease; ACEI, angiotension converting enzyme inhibitor ARB, angiotensin receptor blocker; CCB, calcium channel blocker. a For ESRD and residual urine volume, the 10th and 90th percentiles are given. Considerable interest has been directed at the clinical implication of LV remodeling. As a result, the ratio of LVM to LVEDV has been used to describe the various patterns of LV remodeling (22) . The clinical use of this ratio has been largely derived from population studies and studies involving patients treated for hypertension. For example, Cheng et al. (7) examined age-related differences in LV structure and function in 5004 participants without symptomatic cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Increased mass to volume ratio conferred a significant risk for total cardiovascular events, which was strongest among younger patients (,65 years; hazard ratio, 3.69 [1.34 to 10.10]). Similarly, in 4128 patients enrolled in the iPRESERVE Trial, higher LVM/LVEDV ratio was independently associated with the primary composite end point (death or protocol-specific cardiovascular hospitalization) and heart failure events. It is important to note that several of the previous studies have based their observations on two-dimensional echocardiography. Our present results represent a unique dataset, in which cardiac MRI is used to define changes in volume and LVM as a result of frequent hemodialysis. In contrast to most cardiovascular interventions, frequent hemodialysis simultaneously ameliorates hypertension and volume overload in patients with ESRD. Given that both LVM and LVEDV were reduced in patients treated with six times per week hemodialysis, it may not be surprising to note that the ratio was unaffected.
Observational studies in ESRD suggest that solute and water retention contribute to hypertension, LV hypertrophy, and congestive heart failure (23) . The presence of a dilated ventricle (as measured by LVEDV) has been associated with much higher risk than the risk predicted by elevation in LVM alone (2, 3) . These prior studies were derived from echocardiography, which may overestimate LVM and/or cardiac volumes (24) . CMRI used in the daily dialysis trials has obvious advantages for assessing changes in mass and small changes in volume in the ESRD population. LVM assessment by CMRI is independent of chamber dimensions or geometry (25, 26) . In a previous analysis of the daily dialysis trials, we showed that frequent daily hemodialysis potently reduced LVM, with a strong association between changes in BP and changes in LVM. In this analysis, we were interested in further understanding the magnitude of reduction of chamber volumes as measured by changes in both LV and RV volumes after dialysis and contrasting these changes in the daily and nocturnal trials. Our results show that the magnitudes of reductions in LV and RV volumes with frequent daily dialysis were sizeable and comparable with other direct valvular intervention in the non-ESRD population (27) . Patients with larger reductions in LVEDV also tended to have larger reductions in predialysis systolic BP and LVM, further underscoring the fact that the pathophysiologic mechanisms that lead to LV hypertrophy may be inextricably linked to those mechanisms that mediate adverse LV dilation.
Recently, Agarwal et al. (28) showed in a randomized controlled trial that reduction in target postdialysis weight in patients on conventional daily dialysis occurs in conjunction with a substantial fall in systolic and diastolic BPs. More frequent hemodialysis, whether given daily in center or in long-session nocturnal mode, reduced the mean interdialytic weight change and BP. The acute dynamic effects of hemodialysis on LV end diastolic and end systolic dimensions have been measured by Drighil et al. (29) . Seventeen patients were examined by tissue Doppler echocardiography before and after hemodialysis. After hemodialysis, there was a fall in LV end diastolic and end systolic dimensions by 20% and 12%, respectively. Our present results show that frequent daily hemodialysis reduced LV and RV end diastolic dimensions by 11% and 12%, respectively. In the daily trial, both LV and RV volumes were reduced in the six times per week group and occurred in conjunction with reductions in BP. It is logical to assume showed a dynamic direct association between increases in RV pressures (an average increment of 14%) and the extent of interdialytic weight gain. One may infer that the cyclic expansion and contraction of extracellular volume typically seen in conventional hemodialysis is directly transmitted to both LV and RV. Residual urine volume has been shown to be an important determinant of cardiovascular morbidity and mortality in patients with ESRD. The effect of residual urine volume on the pathogenesis of left ventricular hypertrophy has been most extensively studied in patients on peritoneal dialysis (31) . On average, frequent hemodialysis enabled patients with ESRD to preserve cardiac (left-and rightsided) ventricular geometry. We found a more pronounced reduction in LV and RV volumes with frequent relative to conventional hemodialysis among patients with lower levels of residual urine volume. Given that only a minority of patients in the nocturnal trial (27.6%) has minimal residual urine volume, the inclusion of incident patients with ESRD may, in part, explain the lack of effect of nocturnal hemodialysis on cardiac volumes. Patients with little or no residual urine volume may be more susceptible to the adverse cardiovascular effects of volume overload and/or retention of so-called middle molecules-solutes that are less well dialyzed than urea and other lower molecular weight solutes; indeed, these molecules are generally cleared far more efficiently by native kidneys than dialysis in contrast to urea and other smaller, uncharged water-soluble molecules. These analyses shed light on the profound health benefits afforded to patients who retain even slight degrees of residual kidney function relative to those patients who are completely anuric.
Strengths of the current study include the trial designa multicenter randomized clinical trial with a broad range of patients in terms of age, sex, race/ethnicity, vintage, and primary causes of kidney disease as well as blinded centralized assessment of cardiac volumes. Moreover, adherence was excellent in the daily trial (13) and very good in the nocturnal trial (14) . Thus, we endorse both the internal and external validity of our findings. However, there are several important weaknesses inherent in our approach. First, we did not collect data on dietary sodium intake, fluid intake, or ambulatory (continuous) BP, which might have helped to refine our analyses and provide additional detail useful to clinicians. Second, we conducted the MRI measurement at only one time point within the dialysis cycle; repeated scans would have allowed us to refine our estimates. Third, we are limited to ventricular volumes. Assessment of atrial volumes would have been helpful, especially in view of the accentuation of effect on ventricular volumes in those individuals with minimal urine volume. The present study did not aim to relate the intervention-induced changes in cardiac chamber volumes and geometry with clinical events. Nevertheless, in another trial enrolling patients on hemodialysis with dilated cardiomyopathy, a similar magnitude reduction in LVEDV translated into an improvement in overall survival (4) .
In summary, the FHN trials show that frequent in-center hemodialysis results in reductions in LV and RV volumes. This effect was more pronounced in patients with little or no residual urine volume. LV remodeling was unaffected by frequent hemodialysis. The majority of patients randomized to six times per week hemodialysis exhibited either reduction or preservation of LVM, EDV, and ESV. 
